Xenon Pharmaceuticals stock gains on solid August 6 earnings

Published on 09/01/2026 at 20:51 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Xenon Pharmaceuticals stock is trading higher after its August 6, 2026 earnings update showed EPS of -1.11 dollars, a 0.05 dollar beat, and a market cap of 5.82 billion dollars.

XENE, CA98420N1050, Illustration mit AI erstellt.

Xenon Pharmaceuticals Inc. (CA98420N1050) stock was quoted at 60.22 USD, with a market value of 5.82 billion USD and a 52-week range of 35.60 USD to 72.66 USD, as traders assessed the latest earnings update and analyst tone on September 1, 2026.

August 6 set the tone

According to MarketBeat, Xenon Pharmaceuticals last announced quarterly earnings on August 6, 2026 and reported EPS of -1.11 USD, beating the consensus estimate of -1.16 USD by 0.05 USD. The same report put the current fiscal year EPS view at -4.73 USD.

The stock also opened at 60.22 USD on September 1, 2026, above its 200-day moving average of 56.61 USD and below its 50-day moving average of 63.29 USD. That leaves the share price between a 1-year low of 35.60 USD and a 1-year high of 72.66 USD.

Analysts still see upside

MarketBeat also said the consensus rating is Buy, with an average target price of 77.13 USD. In the same note, Royal Bank of Canada kept an Outperform view and trimmed its target to 81.00 USD from 82.00 USD, while Needham cut its target to 78.00 USD from 80.00 USD.

For investors, the comparison that matters is still the same: EPS of -1.11 USD versus -1.16 USD expected on August 6, 2026, alongside a share price of 60.22 USD on September 1, 2026.

Pipeline remains the core asset

Xenon Pharmaceuticals is a clinical-stage biopharmaceutical company focused on ion-channel therapeutics for epilepsy, migraine and neuropathic pain. The business case rests on whether that pipeline can keep translating into clearer earnings and a narrower loss profile.

Price and market value

Xenon Pharmaceuticals stock was at 60.22 USD on September 1, 2026, with a market cap of 5.82 billion USD and a 52-week range of 35.60 USD to 72.66 USD. The shares were also above the 200-day average of 56.61 USD and below the 50-day average of 63.29 USD.